Ask AI
ProCE Banner Activity

CLL Therapy Today: Answers to Your Latest Questions From the Experts

Clinical Thought

Read this commentary with expert insights from oncology pharmacists as they address your questions on the recent updates in the management of chronic lymphocytic leukemia (CLL). Topics include fixed duration therapy with acalabrutinib plus venetoclax with or without obinutuzumab (AV/AVO), treatment strategies after progression on AV/AVO, and the critical role of pharmacists in optimizing adherence and patient outcomes.

Released: July 09, 2025

Expiration: January 08, 2026

Continue Activity View Activity

Share

Provided by

Provided by ProCE, LLC in collaboration with Clinical Care Options, LLC.

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Disclosure

Primary Author

James Davis, PharmD, BCOP: consultant/advisor/speaker: Bristol Myers Squibb, Janssen.

Victoria Nachar, PharmD, BCOP: consultant/advisor/speaker: BeiGene, Genmab, GlaxoSmithKline.